Ronald W. Dollens
Ron Dollens, former CEO of Guidant Corporation, was a catalyst leader of the fields of interventional cardiology and cardiac rhythm management. At Advanced Cardiovascular Systems (ACS), a subsidiary of Eli Lilly and Company, he engineered tremendous growth in the field and innovation in the product line. He was the founding CEO of Guidant in the 1994 split-off from Eli Lilly. Leading through innovation, Guidant developed market leading positions in the largest and fastest growing product segments of his era: implantable cardioverter defibrillators (ICD’s), coronary stents, and cardiac resynchronization therapy defibrillators (CRT-D’s). Guidant’s market capitalization increased 22x under his leadership – selling ultimately for $27 billion in 2006. Mindful that innovation is essential to rising health care and medical technology industry outcomes, Ron holds a strong view that sound public policy is of vital importance to assure proper reward incentives for innovation. He personally applied himself to the work, including as chairman of AdvaMed. As a direct result of his lifetime of work, cardiovascular health outcomes have dramatically improved; and, millions have been relieved of fear and endowed with full life.
Ronald W. Dollens, retired president and Chief Executive Officer of Guidant Corp., a former Chairman, KCI and current chairman of the board of Avanos. Dollens, served as president of medical devices and diagnostics at Eli Lilly & Co and CEO of Guidant when it spun out of Eli Lilly. Dollens is a director of the Regenstrief Foundation. He has been a director for the Alliance for Aging Research, a director of the Eiteljorg Museum in Indianapolis, a trustee of Butler University and is past chairman of the United Way of Central Indiana.
Dollens had an advisory role for the Purdue School of Pharmacy, Duke University’s Pratt School of Engineering and Stanford Advisory Council on Interdisciplinary Biosciences.